HiveBio calls Cohort 1 its inaugural accelerator program.

HiveBio Cohort 1 was the organization’s inaugural accelerator, developed in collaboration with WorldUpstart Impacts, LaunchBio, and HelaPlex. It was for applicants living in the Greater Philadelphia area, with biopharma and drug development listed as eligible company categories. The cohort met virtually and in person during 2025–26, and HiveBio planned nine months of support.

HiveBio announced ten selected startups on April 3, 2025. Its advertised support included one-on-one guidance through commercialization stages, investor access, help with financial projections and capital strategy, and assistance with non-dilutive funding strategy and SBIR/STTR applications. HiveBio later reported that 80% of inaugural cohort startups secured funding and that participating companies collectively raised $3.56M+ during participation, including additional fundraising since September 2025; the reported amount’s currency is not specified.

Cohort 1 required applicants to live in the Greater Philadelphia area. Biopharma and drug development were listed as eligible company categories.

HiveBio advertised one-on-one guidance through commercialization stages, investor access, support with financial projections and capital strategy, and help with non-dilutive funding strategy and SBIR/STTR application development.

HiveBio planned nine months of support for Cohort 1, which met virtually and in person during 2025–26. HiveBio announced ten selected startups on April 3, 2025.

HiveBio reported that 80% of inaugural cohort startups secured funding. It also reported that participating companies collectively raised $3.56M+ during participation, including additional fundraising since September 2025; the cited passage does not specify the currency. These are operator-reported funding outcomes, not a completion rate.